Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › PB-119

PB-119

GLP-1 · s.c. weekly · PegBio

Data cut 12 November 2026 · page built 16 November 2026 · 2 trial arms · 2 trials with results · 2 registered trials · see on the pipeline board

Summary

Also known as
PegBio (PEGylated exenatide)
Mechanism
GLP-1
Route
s.c. weekly
Company
PegBio
Highest development stage
approved
Status (as of data cut)
Approved in China for T2D (November 2025) verify
Next milestone
Obesity development

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity1 phase 2 / signalPhase 2 only
T2D4 approved / in labelNMPA (China), November 2025PegBio HKEX announcement (Nov 2025)
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)150 μg QWt2d china24310——−1.2 vs −0.7—7.4 vs 7.74.2 vs 0.34.8 vs 0.32.9 vs 3.9—press release
Phase 3 monotherapy (NCT04504370)150 μg QWt2d china24137——−1.4 vs −0.62.24.4 vs 7.48.0 vs 0.75.8 vs 0.06.6 vs 1.5—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (11)
  • 150 μg QW · hba1c · publication
    the least squares mean (LSM) change from baseline in HbA1c was −1.36% (95% CI 1.52 to −1.20)
  • 150 μg QW · nausea · Table 4 (safety set; double-blind 24-week period; Visepegena
    Nausea 11 (8.0) 32 1 (0.7)
  • 150 μg QW · vomiting · Table 4 (safety set; double-blind 24-week period; Visepegena
    Vomiting 8 (5.8) 14 0 (0.0)
  • 150 μg QW · ae_dc · publication
    The common cause of treatment discontinuation was AE in three (2.2%) participants of the visepegenatide group
  • 150 μg QW · disc_any · publication
    Six (4.4%) participants received visepegenatide and 10 (7.4%) participants received placebo discontinued the treatment in the double-blinded treatment period.
  • 150 μg QW · sae · Table 4 (safety set; double-blind 24-week period; Visepegena
    Serious Adverse Events (SAEs) 9 (6.6) 10 2 (1.5)
  • 150 μg QW · hba1c · publication
    was −1.25% (95% confidence interval (CI), −1.35 to −1.16) in the visepegenatide group and −0.68% (95% CI, −0.78 to −0.59) in the placebo group.
  • 150 μg QW · disc_any · Results, first paragraph
    During the 24-week double-blind period, 287 (92.6%) participants in the visepegenatide group and 286 (92.2%) participants in the placebo group completed the treatment and entered the extension phase.
  • 150 μg QW · nausea · Table 3, double-blind columns (Visepegenatide N=310, Placebo
    Nausea 13 (4.2) 31 1 (0.3)
  • 150 μg QW · sae · Table 3, double-blind columns
    Serious adverse events (SAEs) 9 (2.9) 10 12 (3.9)
  • 150 μg QW · vomiting · Table 3, double-blind columns
    Vomiting 15 (4.8) 30 1 (0.3)

Registered trials (2)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT04504396
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
T2DPhase 3completed2020-06 → 2022-09620Completed; results not in the atlas yetNCT04504396
PB119
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
T2DPhase 3completed2020-04 → 2022-03273Completed; results not in the atlas yetNCT04504370

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: PB-119. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/pb-119/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.